vs

Side-by-side financial comparison of LESAKA TECHNOLOGIES INC (LSAK) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.

LESAKA TECHNOLOGIES INC is the larger business by last-quarter revenue ($3.0B vs $1.5B, roughly 2.0× BeOne Medicines Ltd.). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 0.0%, a 4.4% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 0.2%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (341.6% CAGR vs 41.2%).

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

LSAK vs ONC — Head-to-Head

Bigger by revenue
LSAK
LSAK
2.0× larger
LSAK
$3.0B
$1.5B
ONC
Growing faster (revenue YoY)
ONC
ONC
+32.6% gap
ONC
32.8%
0.2%
LSAK
Higher net margin
ONC
ONC
4.4% more per $
ONC
4.4%
0.0%
LSAK
Faster 2-yr revenue CAGR
LSAK
LSAK
Annualised
LSAK
341.6%
41.2%
ONC

Income Statement — Q1 FY2027 vs Q4 FY2025

Metric
LSAK
LSAK
ONC
ONC
Revenue
$3.0B
$1.5B
Net Profit
$437.0K
$66.5M
Gross Margin
90.5%
Operating Margin
2.2%
12.4%
Net Margin
0.0%
4.4%
Revenue YoY
0.2%
32.8%
Net Profit YoY
143.8%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LSAK
LSAK
ONC
ONC
Q3 26
$3.0B
Q2 26
$3.1B
Q4 25
$178.7M
$1.5B
Q3 25
$171.4M
$1.4B
Q2 25
$168.5M
$1.3B
Q1 25
$161.4M
$1.1B
Q4 24
$176.2M
$1.1B
Q3 24
$153.6M
$1.0B
Net Profit
LSAK
LSAK
ONC
ONC
Q3 26
$437.0K
Q2 26
$3.6M
Q4 25
$3.6M
$66.5M
Q3 25
$-4.3M
$124.8M
Q2 25
$-28.4M
$94.3M
Q1 25
$-22.1M
$1.3M
Q4 24
$-32.5M
$-151.9M
Q3 24
$-4.5M
$-121.3M
Gross Margin
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
31.4%
90.5%
Q3 25
30.9%
86.1%
Q2 25
28.9%
87.5%
Q1 25
27.5%
85.2%
Q4 24
25.7%
85.8%
Q3 24
22.6%
83.0%
Operating Margin
LSAK
LSAK
ONC
ONC
Q3 26
2.2%
Q2 26
1.2%
Q4 25
1.2%
12.4%
Q3 25
0.2%
11.5%
Q2 25
-16.7%
6.7%
Q1 25
0.4%
1.0%
Q4 24
0.3%
-7.0%
Q3 24
-0.0%
-12.0%
Net Margin
LSAK
LSAK
ONC
ONC
Q3 26
0.0%
Q2 26
0.1%
Q4 25
2.0%
4.4%
Q3 25
-2.5%
8.8%
Q2 25
-16.9%
7.2%
Q1 25
-13.7%
0.1%
Q4 24
-18.4%
-13.5%
Q3 24
-3.0%
-12.1%
EPS (diluted)
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
$0.04
$0.05
Q3 25
$-0.05
$0.08
Q2 25
$-0.40
$0.06
Q1 25
$-0.27
$0.00
Q4 24
$-0.40
$-0.10
Q3 24
$-0.07
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LSAK
LSAK
ONC
ONC
Cash + ST InvestmentsLiquidity on hand
$1.5B
$4.5B
Total DebtLower is stronger
$3.2B
$836.4M
Stockholders' EquityBook value
$4.4B
Total Assets
$11.5B
$8.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LSAK
LSAK
ONC
ONC
Q3 26
$1.5B
Q2 26
$1.2B
Q4 25
$69.5M
$4.5B
Q3 25
$72.2M
$4.0B
Q2 25
$76.5M
$2.8B
Q1 25
$71.0M
$2.5B
Q4 24
$60.6M
$2.6B
Q3 24
$49.7M
$2.7B
Total Debt
LSAK
LSAK
ONC
ONC
Q3 26
$3.2B
Q2 26
$3.4B
Q4 25
$216.8M
$836.4M
Q3 25
$208.1M
Q2 25
$200.8M
Q1 25
$194.7M
Q4 24
$148.7M
Q3 24
$148.5M
Stockholders' Equity
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
$180.6M
$4.4B
Q3 25
$170.4M
$4.1B
Q2 25
$161.6M
$3.8B
Q1 25
$185.2M
$3.5B
Q4 24
$193.3M
$3.3B
Q3 24
$184.2M
$3.4B
Total Assets
LSAK
LSAK
ONC
ONC
Q3 26
$11.5B
Q2 26
$11.7B
Q4 25
$704.6M
$8.2B
Q3 25
$652.9M
$7.6B
Q2 25
$653.7M
$6.3B
Q1 25
$649.2M
$5.8B
Q4 24
$640.6M
$5.9B
Q3 24
$551.9M
$5.8B
Debt / Equity
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
1.20×
0.19×
Q3 25
1.22×
Q2 25
1.24×
Q1 25
1.05×
Q4 24
0.77×
Q3 24
0.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LSAK
LSAK
ONC
ONC
Operating Cash FlowLast quarter
$417.3M
Free Cash FlowOCF − Capex
$379.8M
FCF MarginFCF / Revenue
25.4%
Capex IntensityCapex / Revenue
2.5%
Cash ConversionOCF / Net Profit
6.28×
TTM Free Cash FlowTrailing 4 quarters
$941.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
$-10.9M
$417.3M
Q3 25
$8.9M
$402.6M
Q2 25
$-9.1M
$263.6M
Q1 25
$10.7M
$44.1M
Q4 24
$-9.2M
$75.2M
Q3 24
$-4.1M
$188.4M
Free Cash Flow
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
$-14.8M
$379.8M
Q3 25
$4.9M
$354.5M
Q2 25
$-13.2M
$219.8M
Q1 25
$7.8M
$-12.3M
Q4 24
$-15.5M
$-17.3M
Q3 24
$-8.1M
$54.7M
FCF Margin
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
-8.3%
25.4%
Q3 25
2.9%
25.1%
Q2 25
-7.8%
16.7%
Q1 25
4.9%
-1.1%
Q4 24
-8.8%
-1.5%
Q3 24
-5.3%
5.5%
Capex Intensity
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
2.2%
2.5%
Q3 25
2.3%
3.4%
Q2 25
2.4%
3.3%
Q1 25
1.7%
5.0%
Q4 24
3.6%
8.2%
Q3 24
2.6%
13.3%
Cash Conversion
LSAK
LSAK
ONC
ONC
Q3 26
Q2 26
Q4 25
-2.99×
6.28×
Q3 25
3.22×
Q2 25
2.79×
Q1 25
34.71×
Q4 24
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons